Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii

Journal of Antimicrobial Chemotherapy

Volumn 50, Issue 6, 2002, Pages 981-987

  Djurkovic Djakovic, Olgica ^a   Milenković, Vladimir ^b   Nikolić, Aleksandra ^a   Bobić, Branko ^a   Grujić, Jelica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Biozentrum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ATOVAQUONE; CLINDAMYCIN; CORTISONE ACETATE; DEXAMETHASONE; PANKLAV;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CYST; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; LETHARGY; MOUSE; MOUSE STRAIN; NONHUMAN; SURVIVAL; TOXOPLASMA GONDII; TOXOPLASMOSIS; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 12244279339     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf251     Document Type: Article

References (26)

1. Luft, B. J. & Remington, J. S. (1992). Toxoplasmic encephalitis in AIDS. Clinical Infectious Diseases 15, 211-22.
2. Haverkos, H. W. & the TE Study Group. (1987). Assessment of therapy for toxoplasma encephalitis. American Journal of Medicine 82, 907-14.
3. Leport, C., Raffi, F., Matherson, S., Katlama, C., Regnier, B., Saimot, A. G. et al. (1988). Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. American Journal of Medicine 84, 94-100.
4. Araujo, F. G., Slifer, T. & Remington, J. S. (1994). Rifabutin is active in murine models of toxoplasmosis. Antimicrobial Agents and Chemotherapy 38, 570-5.
5. McCabe, R. E. (2001). Antitoxoplasma chemotherapy. In Toxoplasmosis (Joynson, D. H. M. & Wreghitt, T. G., Eds), pp. 319-60. Cambridge University Press, Cambridge, UK.
6. McFadden, D. C., Tomavo, S., Berry, E. A. & Boothroyd, J. C. (2000). Characterization of cytochrome b from Toxoplasma gondii and Qo domain mutations as a mechanism of atovaquone-resistance. Molecular and Biochemical Parasitology 108, 1-12.
7. Araujo, F. G., Huskinson-Mark, J., Gutteridge, W. E. & Remington, J. S. (1992). In vitro and in vivo activities of the hydroxy-naphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrobial Agents and Chemotherapy 36, 326-30.
8. Ferguson, D. J., Huskinson-Mark, J., Araujo, F. G. & Remington J. S. (1994). An ultrastructural study of the effect of the treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii. International Journal of Experimental Pathology 75, 111-6.
9. Gormley, P. D., Pavesio, C. E., Minnasian, D. & Lightman, S. (1998). Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease. Investigative Ophthalmology and Visual Science 39, 1171-5.
10. Sordet, F., Aumjaud, Y., Fessi, H. & Derouin, F. (1998). Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis. Parasite 5, 223-9.
11. Araujo, F. G., Lin, T. & Remington, J. S. (1993). The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine. Journal of Infectious Diseases 167, 494-7.
12. Romand, S., Della Bruna, C., Farinotti, R. & Derouin, F. (1996). In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma grondii. Antimicrobial Agents and Chemotherapy 40, 2015-20.
13. Kovacs, J. & the NIAID Clinical Centre Intramural AIDS Program. (1992). Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. Lancet 340, 637-8.
14. Katlama, C., Mouthon, B., Gourdon, D., Lapierre, D., Rousseau, F. & the Atovaquone Expanded Access Group. (1996). Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. AIDS 10, 1107-12.
15. Torres, R. A., Weinberg, W., Stansell, J., Leoung, G., Kovacs, J., Rogers, M. et al. (1997). Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group. Clinical Infectious Diseases 24, 422-9.
16. Dannemann, B. R., Israelski, D. M. & Remington, J. S. (1988). Treatment of toxoplasmic encephalitis with intravenous clindamycin. Archives of Internal Medicine 148, 2477-82.
17. Dannemann, B., McCutchan, J. A., Israelski, D., Antoniskis, D., Leport, C., Luft, B. et al. (1992). Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Annals of Internal Medicine 116, 33-43.
18. McMaster, P. R. B., Powers, K. G., Finerty, J. F. & Lunde, M. N. (1973). The effect of two chlorinated lincomycin analogues against acute toxoplasmosis in mice. American Journal of Tropical Medicine and Hygiene 22, 14-7.
19. Araujo, F. G. & Remington, J. S. (1974). Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrobial Agents and Chemotherapy 5, 647-51.
20. Filice, G. A. & Pomeroy, C. (1991). Effect of clindamycin on pneumonia reactivation of Toxoplasma gondii infection in mice. Antimicrobial Agents and Chemotherapy 35, 780-2.
21. Vuković, D., Djurković-Djaković, O., Kovačević, S., Bobić, B., Nikolić, A., Todorović, V. et al. (1997). Effect of clindamycin in a murine model of acute toxoplasmosis. Clinical Microbiology and Infection 3, 89-94.
22. Djurković-Djaković, O., Nikolić, T., Robert-Gangneux, F., Bobić, B. & Nikolić, A. (1999). Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis. Antimicrobial Agents and Chemotherapy 43, 2240-4.
23. Howe, D. K. & Sibley, L. D. (1995). Toxoplasma gondii is comprised of three clonal lineages: correlation of parasite genotype with human disease. Journal of Infectious Diseases 172, 1561-6.
24. Djurković-Djaković, O. & Milenković, V. (2001). Murine model of drug-induced reactivation of Toxoplasma gondii. Acta Protozoologica 40, 99-106.
25. Odaert, H., Soete, M., Fortier, B., Camus, D. & Dubremetz, J. F. (1996). Stage conversion of Toxoplasma gondii in mouse brain during infection and immunodepression. Parasitology Research 82, 28-31.
26. Dubey, J. P. (1997). Bradyzoite-induced murine toxoplasmosis: stage conversion, pathogenesis, and tissue cyst formation in mice fed bradyzoites of different strains of Toxoplasma gondii. Journal of Eukaryotic Microbiology 44, 592-602.